Company Shanghai Allist Pharmaceuticals Co., Ltd.

Equities

688578

CNE100005XJ7

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Shanghai Allist Pharmaceuticals Co., Ltd.

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
56.86 ^CNY	-0.68%		-4.60%	+36.49%

May. 09	Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib	MT
Apr. 25	Shanghai Allist Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shanghai Allist Pharmaceuticals Co Ltd is a China-based company focusing on the field of tumor treatment. The Company has built a research and development pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. The Company has established a complete new drug research and development system, covering all aspects of lead drug discovery and optimization, candidate drug evaluation and establishment, drug preclinical and clinical research, drug registration and application, industrialization and commercialization. The Company has a number of research pipeline projects under development, such as vometinib. Its drugs are used in the fields of blood pressure reduction, anti-tumor, anti-diabetic and gastric acid related diseases.

Number of employees: 1,044

CNY in Million	2022	Weight	2023	Weight	Delta
Anti-tumor 98.0 %	790	99.9 %	1,978	98.0 %	+150.22%
Technical Licensing 2.0 %	1	0.1 %	41	2.0 %	+6,442.52%
Other Business 0.0 %	0	0.0 %	0	0.0 %	+9.71%

CNY in Million	2022	Weight	2023	Weight	Delta
China 98.2 %	791	100.0 %	1,983	98.2 %	+150.68%
Overseas 1.8 %	-	-	35	1.8 %	-

Managers	Title	Age	Since
Jin Hao Du CEO	Chief Executive Officer	70	04-03-21
Feng Xu BRD	Director/Board Member	59	16-12-31
Jie Hu BRD	Director/Board Member	49	19-06-24
Shuo Li SEC	Corporate Secretary	34	20-03-10

Members of the board	Title	Age	Since
Jun Yan BRD	Director/Board Member	42	19-11-27
Jin Hao Du CEO	Chief Executive Officer	70	04-03-21
Rong Gang Xie BRD	Director/Board Member	39	19-11-27
Ju Qi BRD	Director/Board Member	72	19-11-27
Jie Hu BRD	Director/Board Member	49	19-06-24
Guo Yang BRD	Director/Board Member	35	11-12-31
Jia Yu Yang BRD	Director/Board Member	45	19-11-27
Chao Lu BRD	Director/Board Member	42	19-11-27
Sheng Tao Zhu BRD	Director/Board Member	46	19-11-27
Jia Qi Jin BRD	Director/Board Member	36	22-03-27

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	450,000,000	153,132,053 ( 34.03 %)	0	34.03 %

Name	Equities	%	Valuation
Hainan Shiyu Investment Management Co., Ltd. 10.88 %	22,499,920	10.88 %	193 M ¥
LAV Management Co., Ltd. 5.894 %	12,187,500	5.894 %	104 M ¥
Yan Qin Zhi 3.183 %	6,581,176	3.183 %	56 M ¥
Xiao Fa Chen 3.168 %	6,551,374	3.168 %	56 M ¥
Aegon-Industrial Fund Management Co., Ltd. 2.922 %	6,041,082	2.922 %	52 M ¥
Penghua Fund Management Co., Ltd. 2.267 %	4,687,379	2.267 %	40 M ¥
Jian Xin Huang 1.820 %	3,762,975	1.820 %	32 M ¥
Wei Sun 1.480 %	3,060,000	1.480 %	26 M ¥
Bosera Asset Management Co., Ltd. 1.340 %	2,770,425	1.340 %	24 M ¥
Yinhua Fund Management Co., Ltd. 0.9967 %	2,060,972	0.9967 %	18 M ¥

Name	Equities	%	Valuation
ARRIVENT BIOPHARMA, INC. 3.81%	1,276,250	3.81%	19,832,925 $

Shanghai Allist Pharmaceuticals Co., Ltd.

26 Lingxiaohua Road Zhoupu Town

201203, Shanghai

http://www.allist.com.cn

address Shanghai Allist Pharmaceuticals Co., Ltd.(688578)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

56.86

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.	+36.49%	3.53B
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs